Can ClearPoint Neuro (CLPT) Stock Reach $25?

ClearPoint Neuro, Inc. (NASDAQ: CLPT), a commercial-stage medical device company that develops MRI-guided platforms for minimally invasive brain procedures and cell and gene therapy delivery, has seen its shares fall sharply from their 52-week high of roughly $30 to the mid-teens. With the stock now trading near $15, the question many investors are asking is whether CLPT can climb back toward $25 — a level that aligns closely with several Wall Street price targets.

Key Takeaways

• The selected price target is $25, roughly 60% above recent trading levels near $15 and below the stock's 52-week high of $30.10.
• Wall Street consensus is a Strong Buy, with analyst price targets ranging from $22 to $30 and averages clustered near $23.50 to $25.
• The strongest bullish catalysts are expanding biopharma partnerships, notably uniQure's (QURE) Huntington's disease program and Aspen Neuroscience's Parkinson's cell therapy.
• Key obstacles include persistent net losses, negative cash flow, a recent revenue guidance cut, and elevated short interest.
• Reaching $25 likely depends on revenue reacceleration and tangible progress from gene therapy partners rather than valuation expansion alone.

Company Overview

ClearPoint Neuro develops and commercializes the ClearPoint system, which enables surgeons to perform minimally invasive procedures in the brain under direct, intra-procedural MRI guidance. The platform includes hardware such as a head-fixation frame and computer workstation, along with disposables like the SmartFrame trajectory device and SmartFlow cannula. In recent years the company has increasingly positioned itself as an enabler of neuro cell and gene therapy delivery, serving a network of more than 60 biopharma partners.

Current Market Position

CLPT trades near $15, giving the company a market capitalization of roughly $467 million. Over the past year the stock has been highly volatile, ranging from a low of $8.27 to a high of $30.10, with a beta of about 1.27. The company generated trailing twelve-month revenue of approximately $42 million, up more than 25% year over year, but remains unprofitable with a net loss of about $34.6 million over the same period. The company holds roughly $29 million in cash against about $64 million in debt.

Why Investors Are Watching the $25 Level

The $25 mark stands out because it sits squarely within the range of published analyst price targets. Lake Street Capital has maintained a Buy rating with a $25 target, while B. Riley Securities carries a higher $30 objective and Stifel holds a more conservative $22 target. The blended consensus averages near $23.50 to $25, making $25 a natural round-number milestone that reflects what the most optimistic mainstream analysts expect within a twelve-month horizon. Crucially, $25 is not an arbitrary goal — it is a level the stock has already demonstrated it can trade through during the past year's rally toward $30.

What Could Drive the Next Leg Higher

The most visible catalyst for CLPT has been progress among its gene therapy partners. In mid-2026, shares surged roughly 32% after uniQure announced plans for a biologics license application (BLA) submission for AMT-130 in Huntington's disease — a development B. Riley cited when raising its price target from $20 to $30. Separately, partner Aspen Neuroscience received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its Parkinson's disease cell therapy, supporting an expedited review pathway. Because ClearPoint's navigation and delivery tools are used in these procedures, commercial adoption of partner therapies could translate into more durable procedure-based revenue.

The company is also broadening its technology footprint. It received CE Marking for its Velocity Alpha MR high-speed surgical drill system and announced a ten-year focused ultrasound development partnership with Sungkyunkwan University in South Korea, extending its drug-delivery ecosystem. Its acquisition of IRRAS added the IRRAflow product to its neurosurgery portfolio.

What Could Prevent the Move

The path to $25 is not without friction. ClearPoint remains deeply unprofitable, with negative operating cash flow and continued cash burn. Management recently lowered full-year 2026 revenue guidance to a range of $48 million to $52 million, down from a prior $52 million to $56 million, citing a deliberate shift toward higher-return investments. Second-quarter 2026 revenue of roughly $10.9 million also missed analyst consensus estimates.

Investor sentiment shows signs of caution as well. Short interest represents approximately 14% of shares outstanding, and recent corporate insider activity has leaned toward selling. With no earnings and a price-to-sales ratio above 10, the stock's valuation depends heavily on future growth that has not yet fully materialized.

Technical Levels That Matter

From a technical analysis perspective, the $15 area has acted as a battleground, while the prior $30 high represents the major upside reference point. Between those two levels, $20 and $25 function as psychological milestones, with $25 serving as the primary recovery objective in the near-to-intermediate term. A sustained move above the mid-teens would be the first step toward rebuilding momentum, while the $8 to $9 zone marks the lower end of the established range and an important support level.

AI Daily Buy/Sell Signals

Traders monitoring ClearPoint Neuro can complement fundamental research with AI Daily Buy/Sell Signals, a tool from Tickeron that uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals are designed to help investors spot emerging opportunities, track existing positions, and identify changing market trends more efficiently. Exploring automated signal tools can add a systematic layer to a broader investment decision-making process.

Final Assessment

Reaching $25 from current levels appears plausible but far from guaranteed. The strongest argument in favor is analyst conviction and a pipeline of gene therapy partnerships that could eventually convert into recurring, procedure-driven revenue. The primary counterweights are continued losses, a downward revision to near-term guidance, and a valuation that already assumes meaningful future growth. For the target to become realistic, investors would likely need to see revenue reaccelerate, clearer timelines from key partners, and stabilization in the company's cash position. Until those conditions emerge, $25 remains an achievable milestone on paper but one that hinges on execution rather than sentiment alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations